Biocept, Inc. · OTC:BIOCQ
Biocept — Investor Presentation (July 2022)
35 slides from Biocept's investor presentation, Jul 14, 2022
Slide 1: Corporate Overview July 2022
Exhibit 99.1 TM Corporate Overview July 2022 Nasdaq: BIOC www.biocept.com 1 | © 2022 Biocept, Inc.
Slide 2: Forward-Looking Statements
TM Forward-Looking Statements This presentation contains, and any accompanying oral presentation would no doubt contain, forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding Biocept, Inc. and our business. Forward-looking statements includ
Slide 3: Investment Highlights
TM Investment Highlights Ø Pioneering proprietary CNSide™ assay using cerebrospinal fluid (CSF) to test for cancer involvement in the central nervous system (CNS); initial U.S. market opportunity of Dedicated to improving $1.2B outcomes for patients with advanced cancer. Ø Expanding CNSide usage amo
Slide 4: Neuro-Oncology Market Overview
Neuro-Oncology Market Overview 4 | © 2022 Biocept, Inc.
Slide 5: Recent Trends in U.S. Deaths Due to Cancer
TM Recent Trends in U.S. Deaths Due to Cancer Ø Cancer deaths in aggregate declined >25% from 2000 to 2019 due to improved screening, diagnosis and prevention, lower smoking rates, and improved treatments Ø Deaths due to cancer of the brain and other nervous system (ONS) have unfortunately remained
Slide 6: Leptomeningeal Metastases (LM)
TM Leptomeningeal Metastases (LM) Ø Cancer cells in the subarachnoid space/CSF Ø Solid and Hematologic malignancies Ø Symptoms: Ø High intracranial pressure and/or spinal cord compression Ø Cranial nerve symptoms Ø Spinal cord and nerve root involvement causing extremity weakness, paresthesia and/or
Slide 7: LM Overall Solid Tumor Incidence
TM LM Overall Solid Tumor Incidence 3-8% of solid tumor patients will be diagnosed with LM during the course 1-3 of their illness On average, leptomeningeal metastasis is detected 3.5X 20% of cancer patients 4-8 demonstrated LM at autopsy more frequently at autopsy than it is diagnosed clinically 40
Slide 8: LM Unmet Clinical Needs
TM LM Unmet Clinical Needs 5 6,7,8 MRI Imaging CSF Cytology 5-8 Ø Underdiagnosed Ø MRI: low positive predictive value Ø Cytology: low overall sensitivity 3 9 NSCLC 1,2,3,4,9 Breast Ø Undertreated Ø Average survival w/o therapy: 4-6 weeks Ø Average survival w/ therapy: 2-4 months Ø Average survival w
Slide 9: 2022 Independent Market Research – U.S.
TM 2022 Independent Market Research – U.S. For LM: For PBM: Diagnosis and Diagnosis and Therapy Selection Therapy Selection CNSide TAM Literature Market Total Segment: Total Segment: $160M $287M (# of patients/year) Sources Research Diagnosis TAM parenchymal brain metastases 112,000 101,800 For PBM:
Slide 10: CNSide Assay Technology, Attributes, and Data
CNSide Assay Technology, Attributes, and Data 10 | © 2022 Biocept, Inc.
Slide 11: First commercially available real time method to measure CNS biomarker status
TM First commercially available real time method to measure biomarker status of CNS Ø Intended to determine the presence, quantity, and characterization of malignant cells in CSF Ø Currently performed primarily for suspicion of or diagnosis for LM * CLIA-Validated Test for Metastatic Carcinomas ü Se
Slide 12: CNSide Identifies Biomarkers & Drug Targets in CSF
TM CNSide Identifies Biomarkers & Drug Targets in CSF Ø Tumor cells circulating in blood (CTCs) can infiltrate the CSF (a cul-de-sac) forming the basis for CNS metastasis Ø ctDNA and ctRNA derived from tumors can be shed into blood or CSF as cells die, but they do not confirm metastasis Ø Biocept an
Slide 13: CNSide Addresses Several Unmet Clinical Needs
TM CNSide Addresses Several Unmet Clinical Needs Is there TARGET Is there TUMOR Detection of LM can be improved using cell capture technology Therapeutic target selection can be informed by multiplexing cellular and molecular assays on single samples Is there TREND Quantifying results for longitudin
Slide 14: Biocept CNSide Proprietary Technology and Workflow
TM Biocept CNSide Proprietary Technology and Workflow* Patented Microfluidic Patented Antibody Cocktail Immunocytochemistry Tumor Cell Isolation Channel and FISH Tumor Cell Detection CTC Workflow MET FISH EGFR, KRAS, BRAF qPCR Actionable NGS Cell-free Sensitivity Enhancing Switch Mutation lung and b
Slide 15: Biocept IP Portfolio – Patents Issued Worldwide
TM Biocept IP Portfolio – 42 Patents Issued Worldwide Family 1 MicroChannel for CTC Capture Expire Issued in US (3), China (3), EU PTO, Hong Kong (3), Japan, S. Korea, Canada ► Recovery of Rare Cells using Microchannel 2025-2027 ► Device for Cell Separation & Analysis Family 2 Sub 1) Issued in US (3
Slide 16: CNSide Publications, Posters, and Abstracts
TM CNSide Publications, Posters, and Abstracts Eight Published CNSide Documents to Date 16 | © 2022 Biocept, Inc.
Slide 17: AAN April 2022: Longitudinal Use in Multiple Tumor Types
TM AAN April 2022: Longitudinal Use in Multiple Tumor Types & Longitudinal Genetic Heterogeneity of HER2 Status 17 | © 2022 Biocept, Inc.
Slide 18: Case Study Demonstrating CNSide Utility
TM 1 Case Study Demonstrating CNSide™ Utility 40-year-old Female • Breast Cancer Primary Tumor • Diagnosed with LM OFF TREATMENT ON TREATMENT Cells Cells Downtrend Uptrend 18 | © 2022 Biocept, Inc. 1 Sharma Et Al. Poster Presented at the Annual meeting for the American Association of Neurology (2022
Slide 19: Promising Early Commercial Adoption of CNSide
TM Promising Early Commercial Adoption of CNSide Unique Ordering Physicians 70 CNSide Order Trend 60 50 350 40 300 30 20 250 10 0 1Q'20 2Q'20 3Q'20 4Q'20 1Q'21 2Q'21 3Q'21 4Q'21 1Q'22 200 Unique Ordering Clients 150 50 45 40 100 35 30 25 50 20 15 0 10 5 1Q'20 2Q'20 3Q'20 4Q'20 1Q'21 2Q'21 3Q'21 4Q'2
Slide 20: FORESEE Clinical Trial
FORESEE Clinical Trial A Prospective, Multi-Institution Study Led by Northwestern University 20 | © 2022 Biocept, Inc.
Slide 21: Biocept's Clinical Trial - FORESEE Study
TM Biocept’s Clinical Trial - FORESEE Study (NCT#: NCT05414123) Objectives: Ø To determine the impact of CNSide in managing Leptomeningeal Metastasis in patients with Breast or Non-Small Cell Lung Cancer Ø Assess correlation of CSF Tumor cells with clinical response Ø Evaluate CNSide in helping to d
Slide 22: FORESEE Trial Schema
TM FORESEE Trial Schema Ø CNSide, imaging, CSF cytology and clinical results collected at baseline and 3 consecutive time points Ø Tumor cell detection by CNSide will be correlated with response to treatment Ø Impact of CNSide on treatment decision making will be assessed via physician questionnaire
Slide 23: The Opportunity
The Opportunity Building shareholder value with CNSide 23 | © 2022 Biocept, Inc.
Slide 24: CNSide Commercial Strategy
TM CNSide Commercial Strategy Expand CNSide Usage Among Thought-Leaders 1 Ø Generate further engagement, experience, and advocacy for CNSide with this small core of experts and leaders Develop the Market 2 Target Market Ø Expand adoption through publication of FORESEE and company-sponsored investiga
Slide 25: 2022 Quantitative Market Research
TM 2022 Quantitative Market Research Key Survey Findings from 150 Medical Oncologists A majority are highly likely to use CNSide for diagnosis and therapy choice and more than half are highly likely to use CNSide for monitoring LM and parenchymal brain metastases Diagnosis & Therapy Choice Disease M
Slide 26: Biocept in the CSF Liquid Biopsy Market
TM Biocept in the CSF Liquid Biopsy Market Leptomeningeal Metastasis 1 Establish CSF beachhead in area with critical unmet needs Ø Significantly advance patient care and management 1 Ø >200,000 with CNS involvement PBM & Gliomas 2 4 POTENTIAL Expand to other neuro-oncology indications Ø Parenchymal
Slide 27: CNSide Biopharma Services – Market Opportunity for CNS Metastases
TM CNSide Biopharma Services – The Market Opportunity for CNS Metastases Key Catalysts for Growth CNS Metastases Studies Initiated from 2003-2022* Ø Incidence of brain metastases is rising as result of increased survival and 300 improved prognosis (~30% of patients) à Data from autopsy cohorts 275 1
Slide 28: Biopharma Neuro-Oncology Services Pipeline
TM Biopharma Neuro-Oncology Services Pipeline Opportunity Stage Description 51 World Leading Cancer Inst. New Prospect!! • >4 pharma funded IST for ADCs Total Opportunities Breast Research Group (antibody-drug conjugates) in BrCa Top Tier Biopharma New Prospect!! • Several trans. research projects f
Slide 29: Leveraging Expertise to Provide COVID-19 RT-PCR Testing
TM Leveraging Expertise to Provide COVID-19 RT-PCR Testing >920,000+ COVID-19 samples received for SARS-CoV-2 testing since launch in June 2020 Ø Diverse base of business in clinics, skilled nursing and colleges leads to repeat testing per client Ø Fast turnaround times with vast majority of results
Slide 30: COVID-19 Volume Drives Revenue Growth, Reducing Cash Burn
TM COVID-19 Volume Drives Revenue Growth, Reducing Cash Burn Cumulative Samples Received 920,000+ Total Samples Received Medicare Reimbursement June 2020 – May 31, 2022 Ø $100 per test Lab Capacity to Meet Demand Ø COVID-19 volume drove increased capacity Ø Automation and investment in additional mo
Slide 31: The Team
The Team 31 | © 2022 Biocept, Inc.
Slide 32: Leadership Team
TM Leadership Team § Seasoned executive with 35+ years medical device & diagnostics experience Sam Riccitelli § Serial oncology diagnostics entrepreneur Chair, Interim President & CEO § Former COO at Genoptix, Inc. § Broad leadership experience in the US and Latin America with Fortune 100 and early-
Slide 33: Board of Visionaries & Scientific Influencers
TM Board of Visionaries & Scientific Influencers Board of Directors Lead Clinical Advisors Ø Samuel D. Riccitelli Chair, Interim President & CEO Ø David Berz, MD, PhD Ø Marsha A. Chandler, PhD Beverly Hills Cancer Center Director, Chair of Nominating and Governance Committee Chief Medical Officer –
Slide 34: Corporate Priorities
TM Corporate Priorities 1 2 3 4 Establish CNSide as Position Biocept as Facilitate metastatic Initiate FORESEE clinical standard of care for leader in emerging brain cancer therapy validity & utility study diagnosis, identifying category of neurological development by leading to guideline potential
Slide 35: Investment Highlights
TM Investment Highlights Ø Commercializing CNSide assay to test for cancer involvement in CNS; initial U.S. market opportunity of Dedicated to improving $1.2B outcomes for patients with advanced cancer. Ø Expanding CNSide usage among neuro-oncologist KOLs Ø Pursuing CNSide standard of care status to